News

Virginia Catalyst Announces Round 13 of Grant Funding! Could you use $200,000 to $800,000 in a Non-Dilutive Grant?

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 13 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy.

“When you combine world class research with entrepreneurial management and capital, then stir, good things happen,” said Mike Grisham, CEO of Virginia Catalyst. “We are looking for passionate research scientists and entrepreneurial leaders in high-growth life science businesses in Virginia who could use $200,000 to $800,000 in non-dilutive grant funding to further a project that improves human health and advances economic development in the Commonwealth. Our Grant Round 13 is now open, and we strongly encourage interested parties to visit the Virginia Catalyst website and apply.”

Letters of Intent (LOI) must be received by March 1, 2022 at 5:00 PM EST. Projects that meet funding criteria will be invited to submit a full application by April 10, 2022. Applications will be reviewed and scored by an independent review team of scientists, venture capitalists and CEOs of Virginia-based life science companies. The top eight applicant teams will be invited to present their proposal the week of May 16, 2022. Awards will be announced at the end of May 2022. The LOI submission form, along with funding criteria and frequently asked questions, are available on the Virginia Catalyst website (www.virginiacatalyst.org/apply.html).

We encourage all interested applicant teams to view our webinar that was co-hosted by Virginia Catalyst and Virginia Bio. This webinar featured an expert panel, facilitated by Mike Grisham, CEO of Virginia Catalyst, to share what it takes to score highly, get funding and position your company and research university for significant follow-on funding from large corporations, venture capitalists, DARPA, NIH and philanthropic foundations. This webinar can be viewed, and the slides downloaded on the home page of Virginia Catalyst at: https://www.virginiacatalyst.org/

Cumulatively through the first twelve funding rounds, Virginia Catalyst has dedicated a total of $24 million for 49 collaborative projects. Together, these projects have created over 200 new jobs and have attracted an additional $250 million of investment capital from venture capital, private equity, corporations and government agencies including DARPA, NIH and NSF. We are proud to continue supporting research investigators and entrepreneurs in achieving value for Virginia and the nation.”

Read more and apply here.

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin